[go: up one dir, main page]

MX2019000863A - Usos de vesicula extracelular que comprende una proteina de fusion que tiene capacidad de union a fc. - Google Patents

Usos de vesicula extracelular que comprende una proteina de fusion que tiene capacidad de union a fc.

Info

Publication number
MX2019000863A
MX2019000863A MX2019000863A MX2019000863A MX2019000863A MX 2019000863 A MX2019000863 A MX 2019000863A MX 2019000863 A MX2019000863 A MX 2019000863A MX 2019000863 A MX2019000863 A MX 2019000863A MX 2019000863 A MX2019000863 A MX 2019000863A
Authority
MX
Mexico
Prior art keywords
evs
engineered
fusion protein
binding capacity
extracellular vesicle
Prior art date
Application number
MX2019000863A
Other languages
English (en)
Inventor
Wiklander Oscar
Görgens André
Gupta Dhanu
Original Assignee
Evox Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evox Therapeutics Ltd filed Critical Evox Therapeutics Ltd
Publication of MX2019000863A publication Critical patent/MX2019000863A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)

Abstract

La presente invención se refiere a vesículas extracelulares (VE) diseñadas para su uso en una variedad de aplicaciones de investigación, diagnostico, formación de imágenes y terapéuticas. Las EV están diseñados para permitir la incorporación y visualización de la superficie de varias proteínas de interés, que pueden ser de naturaleza exógena y/o endógena. El recubrimiento de las EV se logra a través del diseño inventivo de proteínas de los polipéptidos de EV, y la presente invención se relaciona, por lo tanto, con los métodos para el recubrimiento de las EV, las EV en si, así como con los kits, los métodos de detección, las aplicaciones de diagnostico, 10 los métodos de formación de imágenes y los métodos de administración basados en dichas EV diseñadas.
MX2019000863A 2016-07-21 2017-07-21 Usos de vesicula extracelular que comprende una proteina de fusion que tiene capacidad de union a fc. MX2019000863A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1612643.5A GB2552473A (en) 2016-07-21 2016-07-21 Surface decoration of extracellular vesicles
PCT/EP2017/068486 WO2018015539A1 (en) 2016-07-21 2017-07-21 Uses of extracellular vesicle comprising a fusion protein having fc binding capacity

Publications (1)

Publication Number Publication Date
MX2019000863A true MX2019000863A (es) 2019-09-04

Family

ID=56894359

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019000863A MX2019000863A (es) 2016-07-21 2017-07-21 Usos de vesicula extracelular que comprende una proteina de fusion que tiene capacidad de union a fc.
MX2019000861A MX2019000861A (es) 2016-07-21 2017-07-21 Vesicula extracelular que comprende una proteina de fusion que tiene capacidad de union a fc.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019000861A MX2019000861A (es) 2016-07-21 2017-07-21 Vesicula extracelular que comprende una proteina de fusion que tiene capacidad de union a fc.

Country Status (12)

Country Link
US (3) US20230181757A1 (es)
EP (3) EP4299137A3 (es)
JP (4) JP7140743B2 (es)
KR (2) KR20190032479A (es)
CN (2) CN109689098A (es)
AU (2) AU2017300035A1 (es)
BR (2) BR112019001108A2 (es)
CA (2) CA3031183A1 (es)
GB (1) GB2552473A (es)
MX (2) MX2019000863A (es)
SG (4) SG10202100597TA (es)
WO (2) WO2018015539A1 (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012040623A2 (en) 2010-09-24 2012-03-29 The Brigham And Women's Hospital, Inc. Nanostructured gels capable of controlled release of encapsulated agents
GB2552774A (en) * 2016-07-12 2018-02-14 Evox Therapeutics Ltd EV-Mediated delivery of binding protein-small molecule conjugates
GB2552473A (en) * 2016-07-21 2018-01-31 Evox Therapeutics Ltd Surface decoration of extracellular vesicles
WO2018144991A1 (en) 2017-02-03 2018-08-09 The Brigham And Women's Hospital, Inc. Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof
GB201702863D0 (en) * 2017-02-22 2017-04-05 Evox Therapeutics Ltd Improved loading of EVs with therapeutic proteins
GB2597623A (en) 2017-08-07 2022-02-02 Univ California Platform for generating safe cell therapeutics
GB201717446D0 (en) * 2017-10-24 2017-12-06 Evox Therapeutics Ltd Affinity purification of engineering extracellular vesicles
GB201804291D0 (en) * 2018-03-16 2018-05-02 Evox Therapeutics Ltd Cell-mediated exosome delivery
CA3096745A1 (en) 2018-04-04 2019-10-10 Alivio Therapeutics, Inc. Self-assembled gels for controlled delivery of biologics and methods of making thereof
US11266603B2 (en) * 2018-06-28 2022-03-08 Academia Sinica Synthetic polypeptides and uses thereof
AU2019305086B2 (en) 2018-07-20 2024-11-28 The Board Of Trustees Of The Leland Stanford Junior University Soluble polypeptides and methods of using same for inhibiting leukemia inhibitory factor activity
GB201812992D0 (en) 2018-08-09 2018-09-26 Univ Greenwich Liposomes
KR20210045409A (ko) * 2018-08-14 2021-04-26 에버사이트 게엠베하 표적 특이적 세포외 소포
CN108998402B (zh) * 2018-08-28 2020-05-29 江南大学 一种重组枯草芽孢杆菌及其构建方法与应用
WO2020051507A1 (en) 2018-09-06 2020-03-12 The Broad Institute, Inc. Nucleic acid assemblies for use in targeted delivery
CN113271928A (zh) * 2018-10-19 2021-08-17 俄亥俄州国家创新基金会 用于肺部炎症治疗的纳米载体
CN113286826A (zh) * 2018-10-19 2021-08-20 俄亥俄州国家创新基金会 用于针对髓源性抑制细胞的靶向治疗的细胞外囊泡
BR112021007286A2 (pt) 2018-10-19 2021-07-27 Ohio State Innovation Foundation células furtivas terapêuticas nanoprojetadas
EP3880816A1 (en) * 2018-11-16 2021-09-22 Evox Therapeutics Ltd Extracellular vesicles for replacement of urea cycle proteins & nucleic acids
KR102755473B1 (ko) * 2018-12-27 2025-01-14 아케소 바이오파마, 인크. 인간 il-4ra에 대한 항체 및 이의 용도
EP3921432A1 (en) * 2019-02-04 2021-12-15 Codiak BioSciences, Inc. Membrane protein scaffolds for exosome engineering
CA3139287A1 (en) * 2019-05-06 2020-11-12 Thomas MALCOLM Tailored hypoimmune nanovesicular delivery systems for cancer tumors
CA3143327A1 (en) * 2019-06-13 2020-12-17 J. Keith Joung Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
WO2020249757A1 (en) * 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
MA56541A (fr) * 2019-06-21 2022-04-27 Entelexo Biotherapeutics Inc Plateformes, compositions et méthodes d'administration de composés thérapeutiques
US20210093567A1 (en) * 2019-08-06 2021-04-01 Ohio State Innovation Foundation Therapeutic extracellular vesicles
CN114173807B (zh) * 2019-09-02 2024-03-19 庆北大学校产学协力团 包含il-2表面表达-细胞外囊泡作为活性成分的用于预防或治疗癌症的组合物
CN112941028A (zh) * 2019-12-09 2021-06-11 上海细胞治疗集团有限公司 纳米抗体基因修饰的间充质干细胞及其制备方法与应用
AU2021215935A1 (en) 2020-02-05 2022-08-25 Diadem Biotherapeutics Inc. Artificial synapses
US20230149319A1 (en) * 2020-04-13 2023-05-18 City Of Hope Cell-receptor targeted exosomes
CN111544453B (zh) * 2020-04-27 2021-01-22 高连如 一种包含三种血管再生属性的混合干细胞注射液及其制备方法
CN111560352B (zh) * 2020-06-02 2023-03-24 新疆农业大学 一种病毒样囊泡及其制备方法和应用
CN111905105B (zh) * 2020-07-02 2023-05-05 华南师范大学 一种用于癌症靶向治疗的蛋白类纳米药物及其制备方法
CN112111513A (zh) * 2020-07-17 2020-12-22 深圳市第二人民医院 基于外泌体平台的新冠病毒疫苗制备方法
JP2023535726A (ja) 2020-07-24 2023-08-21 ザ ジェネラル ホスピタル コーポレイション 増強ウイルス様粒子および細胞への送達のためのその使用方法
CN113967254B (zh) * 2020-08-04 2022-08-12 华南理工大学 用于多特异性抗体递送的细胞膜包覆型纳米适配子及应用
CA3190722A1 (en) * 2020-08-05 2022-02-10 Ohio State Innovation Foundation Adapter polypeptides and methods of using the same
CN112285195B (zh) * 2020-10-27 2021-08-10 江南大学 一种牛奶外泌体的特征性糖蛋白标志物和牛奶外泌体的特征性标志物分离方法
WO2022149779A1 (ko) * 2021-01-11 2022-07-14 주식회사 엑소코바이오 과발현된 Fc 수용체 또는 이의 일부를 포함하는 엑소좀 및 이의 제조방법
KR102252325B1 (ko) * 2021-01-14 2021-05-14 이장호 태아 유래 태초 면역글로불린을 포함하는 세포외소포의 제조방법
WO2022158836A1 (ko) * 2021-01-21 2022-07-28 주식회사 엑소코바이오 목적 단백질 또는 펩타이드가 융합가능한 Fc 수용체 또는 이의 일부를 포함하는 재조합 엑소좀 및 이의 용도
CA3214655A1 (en) * 2021-04-14 2022-10-20 Joel DE BEER Peptides, nanovesicles, and uses thereof for drug delivery
EP4323396A1 (en) * 2021-04-14 2024-02-21 Anjarium Biosciences AG Fc-derived polypeptides
GB202107182D0 (en) * 2021-05-19 2021-06-30 Evox Therapeutics Ltd Nanoparticle delivery system for production of engineered extracellular vesicles
US20240307317A1 (en) * 2021-06-17 2024-09-19 Thomas Malcolm Tailored hypoimmunenanovesicular delivery systems for cancer tumore, hereditary and infectious diseases
CN115770302A (zh) * 2021-08-13 2023-03-10 南京大学 一种rna递送系统及其应用
CN113599516B (zh) * 2021-08-16 2022-02-18 上海蒙彼利生物技术有限公司 制备外泌体方法及其药物组合物在组织修复中的应用
KR102577502B1 (ko) * 2021-09-08 2023-09-13 주식회사 꿈랩 생체분자의 안정적 발현 및 전달을 위한 플라스미드 플랫폼
CN113897387B (zh) * 2021-10-09 2023-09-05 深圳市汉科生命工程有限公司 一种具有促进毛发再生功能的基因重组msc及其外泌体样纳米材料的制备方法和应用
TWI893561B (zh) * 2021-12-03 2025-08-11 中國醫藥大學 外泌體的生產及其用途
CN114107253B (zh) * 2021-12-17 2024-03-15 复旦大学附属华山医院 一种利用工程细胞进行基因编辑的系统及方法
CN114236113B (zh) * 2021-12-21 2023-07-21 南京农业大学 一种2,4-滴的即用型免疫传感器
WO2023133425A1 (en) * 2022-01-04 2023-07-13 The Broad Institute, Inc. Compositions and methods for delivering cargo to a target cell
US20250231174A1 (en) * 2022-04-07 2025-07-17 The Regents Of The University Of Michigan Methods and devices for screening extracellular vesicles
WO2024064748A2 (en) * 2022-09-20 2024-03-28 North Carolina State University Compositions and methods related to exosomal delivery of therapeutic agents
CN116179582A (zh) * 2022-09-27 2023-05-30 南京医事达生物科技有限公司 一种通用型基因重组蛋白质a亲和纯化填料制备方法和应用
CN117802045A (zh) * 2022-09-30 2024-04-02 北京恩康医药有限公司 一种工程化细胞外囊泡的构建及其应用
CN115873905A (zh) * 2022-11-15 2023-03-31 重庆医科大学附属儿童医院 一种gd2纳米抗体靶向修饰的类外泌体的新型药物载体的制备方法
KR20240158824A (ko) * 2023-04-26 2024-11-05 (주)인엑소플랫 면역글로불린 Fc 영역 또는 이의 변이체를 포함하는 재조합 세포외 소포체 및 이를 이용한 세포외 소포체의 분리 방법
WO2024225847A1 (ko) * 2023-04-28 2024-10-31 연세대학교 산학협력단 유방암 유래 엑소좀 또는 세포외 소포체 분리 방법
GB202307239D0 (en) 2023-05-15 2023-06-28 Evox Therapeutics Ltd Gene therapies for Phenylketonuria
CN119120376A (zh) * 2023-07-10 2024-12-13 浙江大学医学院附属第一医院 一种用于清除致病抗体的嵌合基因工程化纳米囊泡及其制备方法、应用
WO2025068572A2 (en) 2023-09-29 2025-04-03 Evox Therapeutics Limited Polypeptides comprising inteins for engineered evs
WO2025102257A1 (zh) * 2023-11-15 2025-05-22 深圳先进技术研究院 一种靶向子宫工程化细胞外囊泡的制备方法及其应用
CN118725135B (zh) * 2024-09-02 2025-02-07 中国科学院苏州纳米技术与纳米仿生研究所 外泌体的改造方法
CN119019494B (zh) * 2024-10-28 2025-02-07 广州飞来爱生命科技有限公司 一种治疗心梗的脐带间充质干细胞及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4090299A (en) * 1998-05-20 1999-12-06 Sdg, Inc. Liposomal delivery complex
US20040241176A1 (en) * 2000-04-27 2004-12-02 Ap Cells. Inc. Method of producing membrane vesicles
US20070128117A1 (en) * 2003-02-04 2007-06-07 Bracco International B.V. Ultrasound contrast agents and process for the preparation thereof
JP2007295929A (ja) 2006-04-05 2007-11-15 Geno Membrane:Kk イヌＢｓｅｐ遺伝子
JP2010536392A (ja) * 2007-08-30 2010-12-02 ヴィレックス メディカル コーポレイション 抗原性組成物および核酸の標的化送達におけるその使用
JP2010540466A (ja) 2007-09-24 2010-12-24 ザ ユニバーシティ オブ クイーンズランド 分子送達ベシクル
US20130053426A1 (en) 2009-04-17 2013-02-28 Yiqi Seow Composition For Delivery Of Genetic Material
MY162489A (en) * 2010-12-23 2017-06-15 Janssen Biotech Inc ACTIVE PROTEASE-RESISTANT ANTIBODY Fc MUTANTS
JP6199746B2 (ja) * 2011-02-15 2017-09-20 バキシオン セラピューティクス，リミテッド ライアビリティ カンパニー 抗体およびＦｃ含有標的化分子に基づく生理活性分子の標的送達のための細菌ミニ細胞による治療用組成物および方法
GB201121069D0 (en) 2011-12-07 2012-01-18 Isis Innovation Delivery system
GB201121070D0 (en) * 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
EP3335721A1 (en) 2013-04-12 2018-06-20 Evox Therapeutics Limited Therapeutic delivery vesicles
WO2015002956A1 (en) 2013-07-01 2015-01-08 Ohio State Innovation Foundation Exosome delivery system
US10538570B2 (en) * 2013-09-30 2020-01-21 Northwestern University Targeted and modular exosome loading system
JP2016535009A (ja) 2013-10-17 2016-11-10 チルドレンズ ホスピタル ロサンゼルス 抗体依存性エキソソーム治療の方法
WO2015143113A1 (en) * 2014-03-20 2015-09-24 Barb Ariel Cohen Preparations of derived extracellular vesicles, assays, and methods to modify therapeutic outcomes using such preparations
GB2552473A (en) * 2016-07-21 2018-01-31 Evox Therapeutics Ltd Surface decoration of extracellular vesicles

Also Published As

Publication number Publication date
WO2018015535A1 (en) 2018-01-25
AU2017299214A1 (en) 2019-02-07
EP3487528B1 (en) 2023-08-30
CN109689097A (zh) 2019-04-26
EP4299137A3 (en) 2024-04-10
US11236143B2 (en) 2022-02-01
JP2019524745A (ja) 2019-09-05
GB201612643D0 (en) 2016-09-07
US20220098267A1 (en) 2022-03-31
EP3487528A1 (en) 2019-05-29
KR20190032480A (ko) 2019-03-27
MX2019000861A (es) 2019-09-04
CA3031186A1 (en) 2018-01-25
BR112019001108A2 (pt) 2019-07-02
JP2023026440A (ja) 2023-02-24
SG10202100598RA (en) 2021-02-25
US20230181757A1 (en) 2023-06-15
SG11201811151PA (en) 2019-01-30
JP2019523407A (ja) 2019-08-22
EP3487529A1 (en) 2019-05-29
KR20190032479A (ko) 2019-03-27
SG11201811152YA (en) 2019-01-30
AU2017300035A1 (en) 2019-02-07
EP4299137A2 (en) 2024-01-03
BR112019001099A2 (pt) 2019-06-25
JP7140743B2 (ja) 2022-09-21
SG10202100597TA (en) 2021-02-25
JP2022117998A (ja) 2022-08-12
KR102636776B1 (ko) 2024-02-15
CN109689098A (zh) 2019-04-26
CN109689097B (zh) 2023-01-03
WO2018015539A1 (en) 2018-01-25
CA3031183A1 (en) 2018-01-25
JP7254016B2 (ja) 2023-04-07
GB2552473A (en) 2018-01-31
US20200109183A1 (en) 2020-04-09

Similar Documents

Publication Publication Date Title
MX2019000863A (es) Usos de vesicula extracelular que comprende una proteina de fusion que tiene capacidad de union a fc.
TR201809571T4 (tr) Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri.
MX2023007211A (es) Anticuerpos antimiostatina y metodos de uso.
WO2013003641A3 (en) Serpin fusion polypeptides and methods of use thereof
MX2022001134A (es) Proteinas quimericas de factor viii y usos de estas.
WO2013142859A3 (en) Fusion proteins of superfolder green fluorescent protein and use thereof
MX2021012047A (es) Polipeptidos de fusion de serpina y metodos para utilizar los mismos.
IN2013MN02442A (es)
WO2015126480A3 (en) Self-assembling underwater adhesives
MX384984B (es) Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas.
WO2011082087A8 (en) Dps fusion proteins for use in vaccines and diagnostics
MX382929B (es) Polipéptido heterodimerizado.
WO2019056023A3 (en) Claudin6 antibodies and methods of treating cancer
JOP20180027A1 (ar) بوليبيبتيدات مخلطة و طرق لتغيير موضع الغشاء فيها
PH12014501363A1 (en) Anticancer fusion protein
MX2015000754A (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
MX2020001223A (es) Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas.
WO2014151834A3 (en) Methods and compositions relating to anti-ccr7 antigen binding proteins
MX2018016417A (es) Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de las mismas.
WO2019090350A3 (en) Wet adhesive peptide materials and their use
PH12021551150A1 (en) Transmembrane domain derived from human lrrc24 protein
WO2015079420A3 (fr) Composition vaccinale pour la prevention et/ou le traitement de leishmanioses, peptides immunogenes et procede d'obtention
LV15035A (lv) Rekombinēta himēriska polipeptīda, kas satur melanokortīna otrā tipa receptoru (MC2R) un melanokortīnu receptoru palīgproteīnu (MRAP), kDNS secības, un tās izmantošana aktīvo vielu testēšanai un terapeitiskiem mērķiem